

**REMARKS**


Claims 1-19 are pending. The Examiner has required restriction to one of the following:

- I. Claims 1-11, drawn to a derivative of Formula (I), and pharmaceutical composition.
- II. Claims 12-19, drawn to a method of treating.


Applicants elect Group I, with traverse.

Applicants respectfully request rejoinder and full examination of the compounds and compositions of group I and the methods of treatment of group II. A search for the compounds of group I would necessarily result in discovery of any methods of treatment utilizing such compounds. Indeed, the search and examination of the compounds and their related methods of use would likely be co-extensive and, in any event, would involve such interrelated art that the search and examination of the both groups can be made without undue burden on the Examiner.

Upon election of Group I, the Examiner has required the election of a single disclosed species. Applicants respectfully elect N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea (Example 1-1, Page 42)



N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea



Claims 1, 2, 4, and 8-19 read on the elected species. [A is ;  
 Q<sub>1</sub> is methylene; Q<sub>2</sub> is CHR<sup>2</sup>; Q<sub>3</sub> is CHR<sup>3</sup>; Q<sub>4</sub> is methylene; Y is NH; m is 0; X is a bond; p is 0;  
 R<sup>1</sup> is optionally substituted aryl (herein phenyl substituted with tri-halo-alkyl and halogen); R<sup>2</sup> is hydrogen; and R<sup>3</sup> is hydroxy].

The afore-mentioned elections are being made solely to comply with, and be fully responsive to, the restriction requirement set forth in the Office Action. Applicants respectfully reserve the right to pursue any non-elected or otherwise unclaimed subject matter in one or more continuation, continuation-in-part, or divisional applications.

Applicants have submitted a petition for an extension of time herewith, but believe that no additional fees are required for consideration and entry of this paper. However, Applicants authorize the Director to charge any required fee or credit any overpayment to Deposit Account No. 04-1105.

Date: **August 11, 2008**

Respectfully Submitted,

By: /Nicholas J. DiCeglie, Jr./

Nicholas J. DiCeglie, Jr.  
 Registration No. 51,615  
 Attorney for Applicant  
 EDWARDS ANGELL PALMER & DODGE LLP  
 P.O. Box 55874  
 Boston, MA 02205  
 Telephone: 212-308-4411  
 Facsimile: 617-227-4420